For more than three decades, pharmaceutical continuous manufacturing (PCM) has been positioned as the future of drug production, offering greater efficiency, agility, and reliability than traditional approaches. But despite compelling proof points and regulatory support, pervasive myths and assumptions have limited adoption. By moving past these legacy perceptions, the industry can reframe PCM for what it is: an integrated system that, when paired with predictive insight and end-to-end process understanding, can transform quality, efficiency, and long-term performance. Read the Article